https://orcid.org/0000-0002-6753-2541
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
In 2010, a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) was introduced in the Brazilian national immunization program; the 3 + 1 dose schedule was replaced by a 2 + 1 dose schedule in 2016. This systematic review presents the latest published evidence (2015–2020) on the impact after 10-year use of PHiD-CV in Brazil from a total of 29 publications. Overall, the PHiD-CV program had a positive impact on the morbidity and mortality associated with invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) in children <5 years-old. A reduction in the vaccine-type invasive disease was observed in all-ages; suggesting indirect protection unvaccinated older children and adults. The occurrence of non-vaccine type disease was evidenced in some studies. Higher vaccination coverage is required at national and state level for sustained population impact. Given the change in the vaccination schedule and the dynamics of pneumococcal disease epidemiology, continuous surveillance is warranted.
GSK Study identifier: HO-18-19438
Acknowledgments
The authors would like to thank Business & Decision Life Sciences platform for editorial assistance and publication coordination, on behalf of GSK. Pierre-Paul Prevot coordinated manuscript development and editorial support. The authors also thank Amrita Ostawal (Arete Communication UG, Berlin, Germany) for medical writing support.
Disclosure of potential conflict of interests
AGH was a post-graduate at Imperial College London and external consultant at GSK Vaccines Panama during the preparation of this work and became a GSK Vaccines employee during the publication development. RDA was an employee of GSK Vaccines during the preparation of this work and became an employee of Cevaxin during the publication development phase. AA was a third-part employee for GSK during the preparation of this work. EB was an GSK employee during the preparation of this study. OC and MP are employees of GSK.
Supplementary material
Supplemental data for this article can be accessed on the publisher’s website at https://doi.org/10.1080/21645515.2021.1879578.
Contributorship
All authors participated in the design or implementation or analysis, and interpretation of the study; and the development of this manuscript. All authors had full access to the data and gave final approval before submission. All authors attest to meeting the ICMJE criteria for authorship.
Trademark
Synflorix is a trademark of GlaxoSmithKline Vaccines.